Light Mode
$0.1595 ↑ +0.0061 (+3.98%) Trading Up from the previous close of $0.1534
-0.64 (-80.60%) / 6M
Momentum, market sentiment, and recent alerts
ATYR reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -84.2%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.